The Efficacy, Safety And Toleration Of CP-866,087 In Pre-Menopausal Women With Female Sexual Arousal Disorder.
NCT ID: NCT00482664
Last Updated: 2010-11-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
84 participants
INTERVENTIONAL
2007-07-31
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1 mg
CP-866,087
Tablets for oral administration
10 mg
CP-866,087
Tablets for oral administration
3 mg
CP-866,087
Tablets for oral administration
Placebo
Placebo
Tablets for oral administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CP-866,087
Tablets for oral administration
CP-866,087
Tablets for oral administration
CP-866,087
Tablets for oral administration
Placebo
Tablets for oral administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* primary female sexual arousal disorder causing distress
* on stable use of oral contraceptives
Exclusion Criteria
* subjects on drugs known to cause Female Sexual Dysfunction
* subjects who have given birth in the last 12 months or who are planning to become pregnant during the study
20 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Dulwich, South Australia, Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia
Pfizer Investigational Site
Aarhus C, , Denmark
Pfizer Investigational Site
Kobenhavn OE, , Denmark
Pfizer Investigational Site
Odense C, , Denmark
Pfizer Investigational Site
Oslo, , Norway
Pfizer Investigational Site
Westville, KwaZulu-Natal, South Africa
Pfizer Investigational Site
Pretoria, , South Africa
Pfizer Investigational Site
Lund, , Sweden
Pfizer Investigational Site
Skövde, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Pfizer Investigational Site
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5051017
Identifier Type: -
Identifier Source: org_study_id